Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/IIa Clinical Trial of AsiDNA in Combination with Chemotherapy (Tumor-DNA Damaging Agent) for the Treatment of Solid Tumors

Trial Profile

A Phase Ib/IIa Clinical Trial of AsiDNA in Combination with Chemotherapy (Tumor-DNA Damaging Agent) for the Treatment of Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etidaligide (Primary) ; Carboplatin; Paclitaxel
  • Indications Advanced breast cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms DRIIV-1b
  • Sponsors Onxeo SA
  • Most Recent Events

    • 13 Nov 2019 According to an Onxeo SA media release, preliminary data from this trial is expected in few weeks.
    • 18 Sep 2019 According to an Onxeo SA media release, the company has initiated the second part of this study. Initial results from the second part of the study are expected at the end of the year.
    • 18 Sep 2019 Results presented in an Onxeo media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top